Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What makes it a fantastic opportunity? Do you know how to value a biotech?
I'm not. Does anyone here even know what they bought?
Fully diluted.
Omg, my 5 year old could understand this, not sure why you can't. Btw, 25mm shares and 34mm warrants (as per 8k) is 59mm, not 42mm. Plus they purchased preferred stock from existing shareholders.
It isn't, closer to 130mm. Emerald is buying at least 25mm shares, 34mm warrants, and the bridge loan already converted to 9mm shares. That's at least 68mm right there.
Weren't we talking FD?
Probably. At this point the company isn't undervalued with respect to rNPV, however that certainly doesn't mean it won't go higher.
So I guessed that the company stated 45mm shares in their latest presentation (February 2017)? I guessed that Series F raised $2mm at $.15 for 13.33mm shares? I guessed that Emerald has committed to purchase at least 25mm shares at $.10, plus 25mm warrants (latest PR actually said 34mm warrants)?
I'm not using it as a negative AT ALL. Someone said fully diluted count was half of what it actually is, but I guess I shouldn't correct them because I have a long position, right?
What exactly did I guess at?
Telling the truth is nonsense?
There were 45 million shares outstanding on a fully converted basis (including warrants and options) as stated in their latest presentation. Series F raised $2mm at $.15/share, so $13.33mm shares, now Emerald is buying 25 million shares and 25 million warrants from Nemus at $.10, PLUS preferred stock from existing holders.
So there will be ~110 million fully diluted, as well as the shares from the bridge loan.
Do you get it?
Huh? 50 million plus the preferred stock. There's ~110 million. I've been following Nemus for a long time and know this company as well as anyone.
The last presentation from February said 45 million shares if fully converted, plus 13.33 million from Series F, and Emerald will have at least 50 million. I don't know how many preferred shares they purchased. They probably needed them to replace the board. Unless the company pays a dividend, they will eventually start to sell. However I don't think that will happen for a long time.
Fully diluted is actually ~110 million including warrants, could be less if some have expired.
YES!
You sound unhinged, Justin.
If Nemus received the $400k by the 16th, and Emerald purchased the preferred stock by the 15th, I think we would have been told. The volume has also been low.
"The closing of the private placement is conditioned on the conversion of all remaining preferred stock of Nemus and satisfactory completion of scientific and operational due diligence. If Nemus does not receive all of the conversion notices or if Emerald does not purchase all the preferred stock of the Certain Preferred Stockholders by January 15, 2018 , does not close the private placement by February 28, 2018 or elects not to proceed with the private placement in its discretion, Emerald has no obligation to make available any amounts then remaining unfunded under the Bridge Loan."
I don't like how this is structured, they should have worked this out before Nemus issued a PR.
I was, most of December.
Good question. The remainder of the bridge loan was due on the 16th, and Emerald was supposed to purchase the preferred stock by the 15th. Nemus should have put out a PR by now.
If Verb is interested in data then I don't think a deal with Intuitive is necessarily out of the question. I'm not saying it will happen. I have no doubt Verb will be disruptive, my brother worked at Google and they're doing incredible work.
You're right. I just thought that Intuitive could increase capital sales with SP, even without competition. For example, I know it's capable of transoral surgeries. I assume multi port has advantages over single port as well?
I know what their partnership is centered around, I read the same PR as you.
I just believe Verb has bigger aspirations than Titan, regarding their technology. Regarding machine learning and data analytics - if they wanted to partner with anyone at this point it would obviously be Intuitive.
Why would they wait? I don't believe it would cannibalize sales of other products. Intuitive wants to control the market - which is why I don't think Titan's strategy of undercutting them will work. I'm not suggesting SP will be a loss leader, but maybe?
I doubt it, Verb is more than just software. Besides, they already have a partnership with Getinge.
I haven't owned or followed InMed in a while, but with Emerald running the show I think Nemus can substantially close the valuation gap.
Emerald's interest in Nemus doesn't have anything to do with Vitalty having an issue with the SEC. I don't think they'll RTO, but Emerald wanting a controlling interest is very encouraging. Btw, Emerald Health Sciences is a private company who is a control person of Emerald Health Therapeutics.
You sold because of the Schneider debacle. Before that you were the biggest pumper of UM IP - saying it was better than anyone else including GW Pharma.
He sold Nemus at a big loss, like Kalytera, but can't move on.
OK, but this is the last time. There's nothing fraudulent about Nemus, and it wasn't a pump and dump. In the last 2+ years only one insider has sold, and he's a still a 10% shareholder. How exactly would Dhillon (not Dillon) steal Murphy and "his" CBD analogue? You mean the IP licensed to Nemus? Emerald is cleaning house, if they don't RTO and just want a controlling interest I think Murphy will be replaced as CEO anyway. I told you that Insys passed (at the time I didn't know it was Insys) - because they went sublingual. That was before UofM created a transmucosal patch which I'm sure is what Emerald is really interested in regarding NB1222/NB2111. No evidence Mallincrockdt (who I also told you about) was interested in a new molecule or even biosynthetic THC. It sounds like they were only interested in making generic dronabinol.
Speaking of Zynerba doing things the right way, their open label FXS data is completely useless, now they have to do a double blind placebo controlled trial.
Wrong, as usual.
Emerald announced a $10mm placement on Jan 3, hopefully we hear something next week.
Thought this was a pr away from a parabolic move?
Why would they need additional employees?
I think they have 3 full time employees, which makes sense considering they're pre-clinical and their R&D is done by the University of Mississippi. All public companies need a whistleblower program.
A reverse split isn't disastrous at all when it's used to uplist. It's inevitable to reach $4/share, however I think the share price will increase substantially before that happens.
Avtar Dhillon of Emerald is also chairman and co-founder of Vitality Biopharma who have a $45mm cap. Nemus should have a similar valuation, if not more. I'm excited to see how this plays out.
Agreed, Nemus should do very well with Emerald on board.
Thanks Quid.
What advantage does SPORT have over Intuitive's single port system?
I have a low opinion of Anton, but he's right that Emerald is getting a great deal.
I didn't read the release, but the market doesn't always get it right. Case in point, the stock had a terrific run since the Fragile X results were released - which supposedly are unreliable and consistent with the placebo effect.
https://twitter.com/AF_biotech/status/913359549666652160